R&D Amortization Rules Explained: Your Money-Saving Guide for 2026 Taxes
R&D amortization rules are changing for the better, bringing the most important financial benefits to businesses across the country. Companies previously had to spread their research and development deductions over five years. Now, immediate expensing is back. The One Big Beautiful Bill Act (OBBBA), signed July 4, 2025, lets businesses fully deduct domestic R&D costs in the year they occur, starting with tax years after December 31, 2024.
Companies focused on state-of-the-art solutions will welcome this reversal of the controversial section 174 R&D amortization requirement. Small businesses with average annual gross receipts of $31 million or less will see even greater benefits. These qualifying companies can apply the change retroactively to taxable years after December 31, 2021. This creates opportunities to file amended returns and receive potential refunds. Businesses with R&D expenses between 2022 and 2024 have choices for their previously capitalized costs. They can deduct the entire unamortized balance in 2025 or split it evenly over 2025 and 2026. In this piece, we’ll explain these new R&D expense amortization rules and help you maximize tax savings for 2026 and beyond.
Understanding Section 174 and the Shift to Amortization
Image Source: Capstan Tax Strategies
Section 174 of the tax code has changed a lot over the last several years. These changes created big challenges for businesses that invest in state-of-the-art research.
What changed under the 2017 Tax Cuts and Jobs Act
The Tax Cuts and Jobs Act (TCJA) of 2017 changed how businesses handle research and experimentation (R&E) expenses. Companies could write off all their R&D costs right away before 2022. This gave them better cash flow and made tax planning easier. Writing off these expenses right away made innovation less expensive after taxes.
The TCJA brought new rules in 2022. Businesses now had to spread these costs over 5 years for domestic research and 15 years for foreign research. The new rules put software development expenses under Section 174 costs. This change helped balance out other TCJA provisions that reduced tax revenue.
How section 174 R&D amortization affected businesses
The switch to spreading out costs hit businesses hard. Companies had to put off more than $59 billion in tax benefits, which cut the value of R&D benefits in half. Research-focused public companies reduced their R&D spending by 11.6% in just the first year.
Cash flow took a big hit at many businesses. They could only deduct 10% of their R&D costs in the investment year instead of the full amount. Many companies cut back on share buybacks and capital spending to deal with higher tax bills.
The complex rules made many businesses stop claiming R&D tax credits from 2022-2024. CPAs told clients that taking the credit meant they would need to spread out R&D expenses. This led to fewer tax deductions and higher taxable income.
IRS guidance and compliance challenges from 2022–2024
The IRS released guidance multiple times about Section 174 R&D capitalization. Notice 2023-63 came out in September 2023 with interim guidance about capitalization and spreading costs. Notice 2024-12 followed in December 2023 to explain things better.
Businesses still had trouble tracking R&D costs and figuring out what counted. Separating domestic and foreign research expenses created extra work, especially for software development. Revenue Procedure 2025-8 came out in December 2024 with new steps for taxpayers who needed to change their accounting methods for Section 174 expenses.
The One Big Beautiful Bill Act and Section 174A
Image Source: MGO CPA
The One Big Beautiful Bill Act (OBBBA) signed on July 4, 2025, brings major tax changes through Section 174A of the Internal Revenue Code that benefit innovative businesses.
Immediate expensing restored for domestic R&D
Businesses can now fully deduct their domestic research and experimental (R&E) costs in the same year they spend them, starting after December 31, 2024. This new rule completely reverses the five-year capitalization requirement from 2022. Companies still have the flexibility to capitalize and spread these costs over 60 months or more if it fits their tax strategy better. Starting in 2025, businesses also get the option to speed up any remaining domestic R&D costs from 2022-2024 over one or two tax years.
Foreign R&D still requires 15-year amortization
The rules look different for foreign research spending. These costs must follow the 15-year amortization schedule that the TCJA put in place. Companies need to carefully track where their R&D happens because of this split system. This approach clearly pushes businesses to keep their research activities in the United States instead of moving them overseas.
Impact on software development and tech companies
Software companies should note that software development costs still count as R&E expenses under both Section 174 and the new Section 174A. The rules have changed from pre-2022 when software development had its own treatment options. Now all software development fits within the R&D framework. This matters for everything from internal systems to commercial products, and tech companies will find significant value in this return to immediate expensing.
Retroactive Relief and Transition Options for 2022–2024
The OBBBA provides relief to businesses that struggled with R&D amortization requirements from 2022 through 2024. Many companies can now recover their lost tax benefits through multiple pathways during this challenging period.
Eligibility for small businesses under $31M gross receipts
Small businesses can apply Section 174A rules retroactively to tax years beginning after December 31, 2021. Your business must meet two critical criteria to qualify:
Your average annual gross receipts should not exceed $31 million for the three tax years before 2025. You need to add your gross receipts from 2022-2024 and divide by three. Your company must not be classified as a tax shelter under Section 448(d)(3) in 2025. Pass-through entities that allocate more than 35% of losses to passive investors typically fall under this classification.
Amending past returns vs. accelerating deductions
Eligible businesses have two distinct options to handle previously capitalized R&D expenses:
Path 1: You can amend returns for 2022-2024 to immediately deduct all domestic R&D costs. This requires consistent amendments across all three years—you cannot pick individual years. You must file amendments before July 6, 2026.
Path 2: You can take “catch-up” deductions by accelerating remaining unamortized amounts. Choose between taking all deductions in 2025 or spreading them evenly over 2025-2026. This method helps you recover deductions without amending multiple returns.
Key deadlines and IRS procedures to follow
July 6, 2026 stands as the deadline for all retroactive elections and amendments. The standard refund statute of limitations might expire earlier for 2022 returns filed before July 6, 2023, so quick action is essential.
Your amendments need a statement titled “FILED PURSUANT TO SECTION 3.03 OF REV. PROC. 2025-28”. Include your taxpayer identification, a declaration of not being a tax shelter, and confirmation of meeting the gross receipts test. The IRS now allows late Section 280C(c)(2) elections related to R&D credits with these amendments.
Taxpayers making method changes instead of amendments need Form 3115. Some 2025 year-of-change elections can use a simplified statement.
Strategic Planning for 2026 and Beyond
Image Source: Tax Foundation
Tax benefits in 2026 will depend on your understanding of the new R&D amortization rules. You need to think over your options carefully.
Choosing between expensing and amortization
Domestic research costs can now be expensed immediately by default. Your business can still choose to capitalize and amortize these expenditures over at least 60 months. The amortization clock starts ticking in the month your company first sees benefits from R&D spending. Your company’s financial situation will determine the best tax planning strategy.
Interaction with R&D tax credit and Section 280C
Your R&D tax credit claims now directly shape your Section 174A deductions. Section 280C(c)(1) requires you to reduce domestic R&D deductions by your claimed credit amount. Companies can avoid this reduction. They need to make a Section 280C(c)(3) election on Form 6765 for a reduced credit – about 79% of the gross credit at the 21% corporate rate. This election must appear on a timely filed return with extensions included. Once made, you typically cannot reverse it. Tax experts often suggest filing a “protective” 280C election even without current credit claims.
State tax conformity and multi-state considerations
States handle R&D expenses differently. Some automatically follow federal changes through “rolling conformity.” Others stick to pre-OBBBA rules. California allows immediate expensing of R&D costs because it follows pre-TCJA rules. Five states – Georgia, Indiana, Mississippi, New Jersey, and Tennessee – have chosen their own path away from federal Section 174 treatment. Your business might face different R&D expense treatments based on location.
Documentation and recordkeeping best practices
The IRS wants better documentation for R&D activities and expenses. Form 6765 will require business-component reporting (Section G) with detailed qualified research activities information by 2026. Your records must show both activity proof (technical challenges, experimentation) and cost connections to qualifying work. Keep records as work happens rather than later, and store them for 5-7 years. The Kyocera case shows why quality documentation matters – poor records led to a $13 million tax loss, about ten times more than the original credit claim.
Conclusion
American businesses focused on innovation can celebrate a major victory with the reinstatement of immediate R&D expense deductions. The tax landscape has improved dramatically compared to 2022-2024 when Section 174 amortization requirements limited cash flow and research investments.
These changes will benefit small businesses the most. Companies with average annual gross receipts under $31 million can completely reverse the financial impact of previous rules through retroactive application. Large corporations will also see substantial benefits, but they must carefully review the difference between domestic and foreign research.
Here’s what your action plan should include. You need to decide whether to amend past returns or speed up unamortized balances into 2025-2026. Next, review the strategic value of immediate expensing versus voluntary amortization based on your projected tax situation. The interaction between R&D tax credits and Section 280C elections needs attention. Note that state tax rules vary greatly by location.
Strong documentation is crucial whatever path you choose. The IRS has stepped up its review of R&D activities, especially with new business-component reporting requirements coming in 2026. Records created at the time that show both qualifying activities and direct cost connections will protect your deductions during audits.
The OBBBA puts America back in a competitive position for research investments. The three-year experiment with amortization proved harmful to innovation. Companies that grasp these rule changes will maximize their tax savings while supporting research activities effectively. Long-term R&D investment planning becomes more reliable now that these changes are permanent, eliminating concerns about future amortization requirements.
Key Takeaways
The One Big Beautiful Bill Act brings major tax relief for R&D-focused businesses, reversing painful amortization rules and restoring immediate expense deductions starting in 2025.
• Immediate R&D expensing returns in 2025 – Domestic research costs can be fully deducted in the year incurred, ending the 5-year amortization requirement that hurt cash flow since 2022.
• Small businesses get retroactive relief – Companies with under $31M average gross receipts can apply new rules back to 2022, creating opportunities for amended returns and significant refunds.
• Foreign R&D still requires 15-year amortization – Only domestic research qualifies for immediate expensing, creating incentives to keep R&D activities within the United States.
• Critical deadline: July 6, 2026 – All retroactive elections and amendments must be filed by this date to capture maximum tax benefits from the rule changes.
• Documentation becomes more critical – Starting 2026, Form 6765 requires detailed business-component reporting, making contemporaneous record-keeping essential for audit protection.
The permanent restoration of immediate R&D expensing represents a major win for American innovation, allowing companies to confidently plan long-term research investments without fear of future amortization requirements.
FAQs
Q1. How do the new R&D amortization rules affect businesses starting in 2025? Starting in 2025, businesses can fully deduct domestic R&D expenses in the year they’re incurred, reversing the previous 5-year amortization requirement. This change allows for immediate tax benefits and improved cash flow for companies investing in research and development.
Q2. What options do small businesses have for handling R&D expenses from 2022-2024? Small businesses with average annual gross receipts under $31 million can either amend their 2022-2024 tax returns to immediately deduct R&D costs or accelerate remaining unamortized amounts in 2025 or spread them over 2025-2026. These options provide flexibility in recovering tax benefits from the previous amortization period.
Q3. How does the treatment of foreign R&D expenses differ from domestic expenses? While domestic R&D expenses can be fully deducted immediately starting in 2025, foreign R&D expenses still require 15-year amortization. This difference incentivizes companies to conduct research activities within the United States rather than overseas.
Q4. What is the deadline for making retroactive elections and amendments under the new rules? The critical deadline for all retroactive elections and amendments is July 6, 2026. This applies to small businesses eligible for retroactive relief and is crucial for capturing maximum tax benefits from the rule changes.
Q5. How do the new rules impact documentation requirements for R&D expenses? Documentation requirements are becoming more stringent, with the IRS demanding robust records of R&D activities and expenses. Starting in 2026, Form 6765 will require detailed business-component reporting, making contemporaneous record-keeping essential for audit protection and demonstrating both qualifying activities and direct cost connections.
